Armor Investment Advisors LLC Sells 45 Shares of Stryker Co. (NYSE:SYK)

Armor Investment Advisors LLC trimmed its stake in Stryker Co. (NYSE:SYK) by 6.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 710 shares of the medical technology company’s stock after selling 45 shares during the quarter. Armor Investment Advisors LLC’s holdings in Stryker were worth $256,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SYK. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the third quarter valued at approximately $36,000. Activest Wealth Management acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $36,000. Crews Bank & Trust acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $39,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker in the third quarter valued at approximately $42,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.2 %

Shares of SYK opened at $392.15 on Tuesday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a market cap of $149.50 billion, a P/E ratio of 50.53, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. The firm’s 50-day simple moving average is $377.23 and its 200 day simple moving average is $365.14. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company posted $3.46 earnings per share. On average, analysts forecast that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Citigroup lifted their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company lifted their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Robert W. Baird lifted their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.